NeoGenomics’ (NEO) Average Rating Reaffirmed at Scotiabank
Scotiabank reaffirmed their average rating on shares of NeoGenomics (NASDAQ:NEO) in a research report sent to investors on Friday. Scotiabank currently has a $24.00 target price on the medical research company’s stock.
A number of other equities analysts also recently weighed in on the stock. BidaskClub raised shares of NeoGenomics from a buy rating to a strong-buy rating in a research note on Saturday, October 27th. Zacks Investment Research downgraded shares of NeoGenomics from a hold rating to a sell rating in a research note on Thursday, July 19th. Benchmark set a $22.00 price target on shares of NeoGenomics and gave the stock a buy rating in a research note on Thursday, November 1st. Raymond James increased their price target on shares of NeoGenomics from $16.00 to $21.00 and gave the stock a buy rating in a research note on Wednesday, October 31st. Finally, First Analysis set a $16.00 price target on shares of NeoGenomics and gave the stock a buy rating in a research note on Tuesday, September 18th. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $20.08.
Shares of NASDAQ NEO opened at $16.08 on Friday. NeoGenomics has a 1 year low of $7.08 and a 1 year high of $19.04. The company has a market cap of $1.50 billion, a P/E ratio of 268.00 and a beta of -0.01. The company has a current ratio of 4.13, a quick ratio of 3.98 and a debt-to-equity ratio of 0.32.
In other news, Director Lynn A. Tetrault sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 14th. The shares were sold at an average price of $16.16, for a total value of $80,800.00. Following the transaction, the director now owns 47,346 shares of the company’s stock, valued at approximately $765,111.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Steven C. Jones sold 100,000 shares of the firm’s stock in a transaction on Monday, November 12th. The shares were sold at an average price of $16.66, for a total transaction of $1,666,000.00. Following the completion of the transaction, the executive vice president now directly owns 241,815 shares in the company, valued at approximately $4,028,637.90. The disclosure for this sale can be found here. In the last three months, insiders sold 4,981,643 shares of company stock worth $83,563,998. Insiders own 12.20% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Glenmede Trust Co. NA purchased a new position in shares of NeoGenomics in the 3rd quarter valued at $114,000. Cubist Systematic Strategies LLC purchased a new stake in NeoGenomics during the 2nd quarter worth $171,000. AMP Capital Investors Ltd purchased a new stake in NeoGenomics during the 2nd quarter worth $178,000. Prudential Financial Inc. purchased a new stake in NeoGenomics during the 3rd quarter worth $224,000. Finally, PNC Financial Services Group Inc. purchased a new stake in NeoGenomics during the 2nd quarter worth $272,000. 80.28% of the stock is currently owned by institutional investors and hedge funds.
NeoGenomics Company Profile
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.